Abstract
A study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / drug therapy*
-
Acquired Immunodeficiency Syndrome / immunology*
-
Acquired Immunodeficiency Syndrome / mortality
-
CD4 Lymphocyte Count
-
Child, Preschool
-
Developing Countries*
-
Drug Therapy, Combination
-
Female
-
Health Resources / supply & distribution*
-
Humans
-
Immune Tolerance*
-
Male
-
Probability
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Survival Analysis
-
Treatment Outcome
Substances
-
Reverse Transcriptase Inhibitors